Krystal Biotech (NASDAQ:KRYS) Releases Earnings Results, Beats Expectations By $0.03 EPS

Krystal Biotech (NASDAQ:KRYS) posted its earnings results on Monday. The company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.03, Briefing.com reports. The firm had revenue of $70.28 million during the quarter, compared to analysts’ expectations of $65.27 million. Krystal Biotech’s quarterly revenue was up 70283900.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.25) earnings per share.

Krystal Biotech Trading Down 2.2 %

NASDAQ KRYS traded down $3.91 during trading hours on Wednesday, reaching $174.70. 337,530 shares of the company’s stock were exchanged, compared to its average volume of 381,679. Krystal Biotech has a one year low of $93.95 and a one year high of $219.34. The firm has a fifty day moving average of $185.89 and a 200-day moving average of $164.54. The stock has a market cap of $4.99 billion, a PE ratio of 95.51 and a beta of 0.84.

Wall Street Analysts Forecast Growth

KRYS has been the subject of a number of recent research reports. Chardan Capital lifted their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday. HC Wainwright restated a “buy” rating and set a $200.00 price objective on shares of Krystal Biotech in a research report on Monday. Stifel Nicolaus reiterated a “buy” rating and issued a $204.00 target price (up previously from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. Finally, Citigroup reiterated a “neutral” rating and set a $204.00 price target (up from $195.00) on shares of Krystal Biotech in a report on Tuesday. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, Krystal Biotech has an average rating of “Moderate Buy” and an average target price of $185.63.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the sale, the insider now directly owns 1,525,882 shares of the company’s stock, valued at approximately $268,189,020.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Julian S. Gangolli sold 20,000 shares of the firm’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $164.13, for a total transaction of $3,282,600.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the sale, the insider now directly owns 1,525,882 shares in the company, valued at $268,189,020.32. The disclosure for this sale can be found here. 14.10% of the stock is owned by insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).